The world of psychedelic medicine is in the midst of a historic renaissance, and at the forefront of this revolution stands a molecule with deep cultural roots and astounding therapeutic potential: ibogaine. Derived from the root bark of the Tabernanthe iboga shrub, ibogaine is rapidly transitioning from an underground, controversial treatment to a legitimate subject of state-funded, rigorous scientific inquiry, driven by a growing desperation to combat the opioid crisis, PTSD, and traumatic brain injury (TBI).
The narrative around ibogaine is complex, a tapestry woven with threads of extraordinary anecdotal success, significant cardiac risk, and restrictive Schedule I classification in the U.S. Yet, recent legislative and research developments suggest a palpable shift, marking a new phase for the powerful psychoactive alkaloid.
Ibogaine for Kratom Addiction: An Emerging Use Case
Ibogaine’s traditional use has been to interrupt opioid addiction, often referred to as a “reset button” for the brain’s opioid receptors. This function has naturally extended to its use against other dependencies that interact with the opioid system, including Kratom addiction. Kratom (Mitragyna speciosa) contains alkaloids like mitragynine, which act as partial opioid agonists, leading to physical dependence and withdrawal symptoms.
While formal, large-scale clinical trials on ibogaine for Kratom use disorder are scarce due to the drug’s Schedule I status, anecdotal reports and observational studies from international clinics (primarily in Mexico and New Zealand) suggest that ibogaine can be highly effective in mitigating the severe withdrawal symptoms and reducing cravings associated with Kratom dependence, much as it does for traditional opioids. The mechanism is believed to be the same: a profound neurochemical reset and a psychological introspection that addresses the root causes of the addiction. However, experts caution that, as with any ibogaine treatment, this must be conducted under strict medical supervision due to cardiac risks.
The Texas-Sized Clinical Research Catalyst: Location and Status
The most significant development is the groundbreaking legislative action taken by the State of Texas. In a move widely regarded as a watershed moment for psychedelic research, Texas has committed substantial public funds to accelerate clinical trials for ibogaine.
In 2025, Texas Governor Greg Abbott signed Senate Bill 2308 into law, which authorizes a significant investment—up to $50 million in state matching funds—to support FDA-approved clinical trials. This funding is specifically targeting the use of ibogaine for treating opioid use disorder, PTSD, and TBI, with a strong emphasis on veterans.
- Clinical Trial Location: The Texas legislation directs the Texas Health and Human Services Commission (HHSC) to request proposals from a consortium composed of a higher education institution, a drug developer, and a hospital. While no final selection has been announced for the lead site, the trials are mandated to be conducted at a Texas-based institution of higher education or hospital. This ensures the state remains the epicenter of the research effort.
- Status: The state has completed the Request for Consortium Proposals (RFP) process as of late summer 2025. The next step is the selection of the lead consortium which will then be tasked with securing an Investigational New Drug (IND) application from the FDA to officially begin clinical trials. The process is expected to take several years before patient enrollment commences.
David Dardashti and the Google Connection
The rise of ibogaine has attracted significant attention from the tech world, often driven by figures seeking radical, non-traditional solutions for mental health and addiction. The mention of David Dardashti often refers to the founder of the Ibogaine Clinic in Playa del Carmen, Mexico, a prominent international clinic that has treated thousands of patients for addiction and trauma. His involvement is primarily in the non-U.S. clinical space, operating where ibogaine treatment is permitted.
The connection to Google is less about direct corporate investment from the search engine itself and more about the personal philanthropic and venture capital interest from its co-founders. Sergey Brin, one of Google’s co-founders, has made multi-million-dollar investments in psychedelic biotech firms, such as Soneira, which are conducting cutting-edge research into the pharmaceutical applications of iboga alkaloids, including those designed to minimize the cardiac risk associated with the natural substance. This private sector engagement from the tech elite is a key driver of funding and legitimacy for the new wave of psychedelic drug development.
Colorado’s Legalization: Decriminalization vs. Regulated Access
Colorado has taken a distinct path regarding ibogaine and other natural medicines, defined by the 2022 voter-approved Natural Medicine Health Act (NMHA). This act does not “legalize” ibogaine for general commercial sale, but rather establishes a two-tiered system:
- Decriminalization for Personal Use: The NMHA removes all state and local criminal penalties for adults (age 21 and older) for the personal use, cultivation, possession, and non-commercial sharing of “natural medicines,” including ibogaine, psilocybin, DMT, and mescaline (excluding peyote). For ibogaine, this means adults will not be arrested or prosecuted by state or local authorities for personal possession. However, federal law still prohibits ibogaine, and the NMHA expressly prohibits the sale of the drug.
- Regulated, Supervised Access (Future Focus): The law paves the way for the future establishment of licensed “Healing Centers” where adults can receive supervised administration of these psychedelics. However, this regulated access is being rolled out in phases.
- Phase 1 (Initial Rollout): Focuses only on psilocybin and psilocin (expected to be operational in 2025).
- Phase 2 (Ibogaine Consideration): The state’s Natural Medicine Advisory Board will consider adopting rules for the licensed and supervised use of ibogaine, DMT, and mescaline no sooner than June 1, 2026.
What the Colorado legalization entails is thus decriminalization for personal use now, and a pathway to future regulated therapeutic access under strict medical and facilitator supervision, contingent on future rulemaking. It is not an immediate free-for-all for ibogaine treatment, particularly given the drug’s inherent safety challenges.
For more information visit www.ibogaineclinic.com